Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00720135 · ClinicalTrials.gov registry record · Phase 1
Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma
A Phase 1 study, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT00720135 is a Phase 1 study that has completed, run by City of Hope Medical Center. The registered enrollment target is 9 participants.
The verdict
NCT00720135, a Phase 1 study, has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
RATIONALE: Biological therapies, such as fusion protein cytokine therapy, may stimulate the immune system in different ways and stop cancer cells from growing. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving fusion protein cytokine therapy together with rituximab may kill more cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of fusion protein cytokine therapy when given after rituximab in treating patients with B-cell non-Hodgkin lymphoma.
Interventions
- BIOLOGICAL rituximab
- OTHER immunohistochemistry staining method
- OTHER pharmacological study
- OTHER flow cytometry
- BIOLOGICAL DI-Leu16-IL2 immunocytokine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2008-01 |
| Est. Completion | 2014-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00720135
The ClinicalTrials.gov registry entry for NCT00720135 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which rituximab is the first listed.
NCT00720135 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00720135 about?
NCT00720135 is a clinical study titled "Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma". RATIONALE: Biological therapies, such as fusion protein cytokine therapy, may stimulate the immune system in different ways and stop cancer cells from growing. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spre...
What is the current status of trial NCT00720135?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2008-01. Estimated completion is 2014-07.
What interventions are being tested in trial NCT00720135?
The interventions under investigation include: rituximab (BIOLOGICAL), immunohistochemistry staining method (OTHER), pharmacological study (OTHER), flow cytometry (OTHER), DI-Leu16-IL2 immunocytokine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00720135?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.